logo-loader

Tarus Therapeutics

Receive alerts
Market:
Unlisted
Market Cap:
-
Price
-
Change
-
52 weeks high
-
52 weeks low
-

In brief

Tarus Therapeutics Inc is a biotechnology company focused on nucleotide metabolism in cancer. The company's lead programs target the immunosuppressive adenosine pathway in the tumor microenvironment (TME) for the treatment of resistant cancers. Adenosine is recognized as a key metabolic checkpoint, and high levels of extracellular adenosine have been evidenced to mediate profound tumor resistance. Selective inhibition of adenosine receptors A2AR and A2BR thus represents a promising approach for cancer immunotherapy. Tarus is developing one of the most comprehensive portfolios of adenosine receptor antagonists in the industry with highly potent and selective antagonists for A2A and A2B receptors, including a novel "dual" antagonist.